<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Glivec; Imatinib" /><meta name="IX" content="Glivec; Imatinib" /><title>Glivec®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5537-glivec.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5537-glivec.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5537-glivec.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a> &gt; <a href="PHP5514-protein-kinase-inhibitors.htm">Protein kinase inhibitors</a> &gt; <a href="PHP5536-imatinib.htm">IMATINIB</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5534-gefitinib.htm" title="Previous: GEFITINIB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5538-lapatinib.htm" title="Next: LAPATINIB">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301024.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Imatinib Mesylate</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20875-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Imatinib</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: I &gt; Interactions of Imatinib</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="PHP5514-protein-kinase-inhibitors.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Protein kinase inhibitors</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs</p></div></li><li><a href="PHP5536-imatinib.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">IMATINIB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Protein kinase inhibitors</p></div></li></ul><ul><li><h3>BNF for Children (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13802-protein-kinase-inhibitors.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Protein kinase inhibitors</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13803-imatinib.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">IMATINIB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Protein kinase inhibitors</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13804-glivec.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Glivec®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Protein kinase inhibitors &gt; IMATINIB</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0009s0024.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Imatinib Mesylate</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; I</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20599-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Imatinib Mesilate</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04902.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Imatinib</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; I &gt; IM</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-I11.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Imatinib Mesylate</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; I</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E22E3E0R0D927.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Imatinib</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; I</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1>IMATINIB</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int933-imatinib.htm">Imatinib</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">see <a title="target-block: IMATINIB NOTES " href="PHP5514-protein-kinase-inhibitors.htm#PHP5519">notes above</a></p></div></div><div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="section: Cytotoxic drugs" href="PHP5180-cytotoxic-drugs.htm">section 8.1</a>; cardiac disease; risk factors for heart failure; history of renal failure; monitor for fluid retention; monitor liver function (see also Hepatic Impairment, below); monitor growth in children (may cause growth retardation); <strong>interactions:</strong> Appendix 1 (imatinib)</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Hepatic impairment </h2> <p class="cT">max. 400 mg daily; reduce dose further if not tolerated</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Renal impairment </h2> <p class="cT">max. starting dose 400 mg daily if creatinine clearance less than 60 mL/minute; reduce dose further if not tolerated</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">manufacturer advises avoid unless potential benefit outweighs risk; effective contraception required during treatment; see also <a title="BNF:target-block: Cytotoxic drugs: Reproductive function" href="PHP5183-side-effects-of-cytotoxic-drugs.htm#PHP5194">Pregnancy and Reproductive Function</a></p></div></div><div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">discontinue breast-feeding</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="topic: Side-effects of cytotoxic drugs" href="PHP5183-side-effects-of-cytotoxic-drugs.htm">section 8.1</a>; also abdominal pain, appetite changes, constipation, diarrhoea, flatulence, gastro-oesophageal reflux, taste disturbance, weight changes, dry mouth; oedema (including pulmonary oedema, pleural effusion, and ascites), flushing, haemorrhage; cough, dyspnoea; dizziness, headache, insomnia, hypoaesthesia, paraesthesia, fatigue; influenza-like symptoms; cramps, arthralgia; visual disturbances, increased lacrimation, conjunctivitis, dry eyes; epistaxis; dry skin, sweating, rash, pruritus, photosensitivity; <em>less commonly</em> gastric ulceration, pancreatitis, hepatic dysfunction (rarely hepatic failure, hepatic necrosis), dysphagia, heart failure, tachycardia, palpitation, syncope, hypertension, hypotension, cold extremities, cough, acute respiratory failure, depression, drowsiness, anxiety, peripheral neuropathy, tremor, migraine, impaired memory, vertigo, gynaecomastia, menorrhagia, irregular menstruation, sexual dysfunction, electrolyte disturbances, renal failure, urinary frequency, gout, tinnitus, hearing loss; skin hyperpigmentation; <em>rarely</em> intestinal obstruction, gastro-intestinal perforation, inflammatory bowel disease, arrhythmia, atrial fibrillation, myocardial infarction, angina, pulmonary fibrosis, pulmonary hypertension, increased intracranial pressure, convulsions, confusion, haemolytic anaemia, rhabdomyolysis, myopathy, aseptic necrosis of bone, cataract, glaucoma, angioedema, exfoliative dermatitis, and Stevens-Johnson syndrome; <em>also reported</em> growth retardation in children</p></div></div><div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p>Chronic phase chronic myeloid leukaemia, <span class="cP">adult</span> 400 mg once daily, increased if necessary to max. 800 mg daily (in 2 divided doses); <span class="cP">child</span> (chronic and advanced phase) 2–18 years 340 mg/m<sup>2</sup> (max. 800 mg) daily (in 1–2 divided doses), increased to 570 mg/m<sup>2</sup> (max. 800 mg) daily if necessary (consult product literature)</p></li><li><p>Accelerated phase and blast crisis chronic myeloid leukaemia, <span class="cP">adult</span> 600 mg once daily, increased if necessary to max. 800 mg daily (in 2 divided doses)</p></li><li><p>Acute lymphoblastic leukaemia, <span class="cP">adult</span> 600 mg once daily</p></li><li><p>Gastro-intestinal stromal tumours, <span class="cP">adult</span> 400 mg once daily</p></li><li><p>Dermatofibrosarcoma protuberans, <span class="cP">adult</span> 800 mg daily in 2 divided doses</p></li><li><p>Myelodysplastic/myeloproliferative diseases, <span class="cP">adult</span> 400 mg once daily</p></li><li><p>Advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia, <span class="cP">adult</span> 100–400 mg once daily</p></li></ul></div></div><div class="cAK"><h2>NICE Technology Appraisals</h2><p>See <a title="Imatinib for chronic myeloid leukaemia (October 2003)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18381">Imatinib for chronic myeloid leukaemia (October 2003)</a></p><p>See <a title="Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)" href="PHP5514-protein-kinase-inhibitors.htm#PHP19125">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)</a></p><p>See <a title="Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (August 2010)" href="PHP5514-protein-kinase-inhibitors.htm#PHP19124">Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (August 2010)</a></p><p>See <a title="Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)" href="PHP5514-protein-kinase-inhibitors.htm#PHP19126">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)</a></p><p>See <a title="Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18380">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</a></p><p>See <a title="Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18379">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</a></p></div></div><div id="pS"><p>Sub-sections</p><div id="PHP5537-glivec" style="margin: 0 0 0 20px;"><h1 class="title">Glivec® <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10261">Novartis</a>)</span><span> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Tablets</strong>, f/c, imatinib (as mesilate) 100 mg (yellow-brown, scored), net price 60-tab pack = £862.19; 400 mg (yellow), 30-tab pack = £1724.39. Label: 21, 27</p><div class="cG"><div class="cE"><h3 class="cT">Counselling</h3> <p class="cT">Tablets may be dispersed in water or apple juice</p></div></div></div></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5534-gefitinib.htm">Previous: GEFITINIB</a> | <a class="top" href="PHP5537-glivec.htm#">Top</a> | <a accesskey="]" href="PHP5538-lapatinib.htm">Next: LAPATINIB</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>